Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Federated Capital Income Fund Class A Shares (CAPAX)

8.08
Net Asset Value
+0.12%
1 Day
-3.23%
Year-to-Date
Overall Morningstar Rating
Conservative allocation
Style or Category
5.5
Sales Expenses
1.08%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks current income and long-term growth of income; capital appreciation is a secondary objective. The fund pursues its investment objective by investing in both equity and fixed-income securities that have relatively high current income potential. Its investment adviser's ("Adviser") process for selecting equity investments attempts to identify mature, mid- to large-cap value companies and securities with high dividend yields that are likely to maintain and increase their dividends. The Adviser selects fixed-income investments that offer high current yields.

Performance

1 month+0.12% 3 years+5.89%
3 months-2.19% 5 years+7.47%
1 year-4.33% Since inception+6.89%
Data through --

Peer Comparisonvs. Conservative allocation

 CAPAXCategory
Performance 5-yr return+7.47%+7.00%
Expense ratio1.08%1.22%
Risk 5 year sharpe ratio1.201.21
Net assets$3.0B$1.6B
Average market cap$27.7B$40.5B
Average P/E21.218.5
Portfolio turnover41%41%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyFederated
Fund manager & tenureMark Durbiano / 18 Years
Minimal initial investment$1,500.00
Minimum IRA investment$250.00

Holdings

Fixed income48.17%
U.S. stock26.26%
Cash10.28%
International stock9.19%
Other6.09%
Top 5 Sectors
Portfolio weighting
Financial service 23.02%
Telecommunication 14.46%
Healthcare 13.21%
Consumer goods 11.64%
Utilities 10.41%
Top 10 Holdings
Portfolio weighting
-- 23.57%
-- 16.94%
-- 4.08%
-- 1.58%
HPT Hospitality Properties Trust1.57%
-- 1.53%
T AT&T1.44%
-- 1.32%
PFE Pfizer1.27%
GSK GlaxoSmithKline1.23%